“Infusion Devices market set to grow to $2.9bn by 2022” says new Visiongain report

16 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Infusion Devices Market Forecast 2018-2028: Syringe, Insulin, Volumetric, Ambulatory, Patient Controlled Analgesia, Implantable, Enteral, Gastroenterology, Diabetes, Analgesia & Pain Management, Chemotherapy, Paediatrics & Neonatology, Hospital, Home Healthcare, Ambulatory Surgical Centres

Infusion devices can be used to treat a wide range of therapeutic areas including analgesia, chemotherapy, diabetes and clinical nutrition, thus making them an invaluable tool in modern medicine. With the advent of modern medical devices, the infusion pump market has become one of the fastest growing drug delivery segments within the market. This rapid growth is projected due to the nature of the illnesses which infusion pumps are used to treat. For example, both the cancer and diabetes markets are on the rise.

The lead analyst of the report commented "With improved regulations, new infusion pump systems hitting the market are safer, more effective, and are becoming increasingly technologically advanced. This has come at a time when a shift between hospital and home care is happening across the world, though particularly in Europe.

The shift in demand from hospitals to home care settings has been particularly advantageous for insulin pumps, patient-controlled analgesia pumps, and ambulatory pumps due to the increased acceptance by patients and focus for the reduction of overall treatment costs associated with longer hospital stays."

Leading companies featured in the report include Baxter International Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, CME Medical UK Ltd., Fresenius SE & Co. KGaA, ICU Medical, Inc., Johnson & Johnson, Moog Inc., Smiths Group plc, Terumo Medical Corporation

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Pharmaceutical Contract Manufacturing market set to grow to $138bn by 2024” says new Visiongain report

The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies.

19 August 2019

Read

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever